Valuation: Precigen, Inc.

Market Cap 2.51B 2.17B 2.03B 1.85B 3.49B 239B 3.55B 23.78B 9.33B 120B 9.41B 9.21B 398B P/E 2026 *
50x
P/E 2027 * 19.2x
Enterprise Value 2.51B 2.17B 2.03B 1.85B 3.49B 239B 3.55B 23.78B 9.33B 120B 9.41B 9.21B 398B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 5.52x
Free-Float
86.44%
Yield 2026 *
-
Yield 2027 * -
1 day-3.18%
1 week+5.90%
Current month+11.64%
1 month+31.58%
3 months+66.27%
6 months+50.21%
Current year+67.46%
1 week 6.55
Extreme 6.55
7.32
1 month 4.81
Extreme 4.81
7.32
Current year 3.04
Extreme 3.04
7.32
1 year 1.72
Extreme 1.72
7.32
3 years 0.65
Extreme 0.6513
7.32
5 years 0.65
Extreme 0.6513
7.32
10 years 0.65
Extreme 0.6513
32.9
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/10/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 01/02/2008
Director/Board Member 78 01/02/2008
Director/Board Member 70 28/11/2011
Date Insider Type Main position Quantity % Market Cap.
8/6/26 A Sell

Chief Operating Officer

-32,739 0.0110%
8/3/26 A Fiscal year

Chief Operating Officer

101,316 0.0339%
7/31/26 A Sell

Chief Financial Officer

-100,000 0.0335%
Change 5-day change 1-year change 3-year change Capi.($)
-3.18%+5.90%+293.26%+360.53% 2.51B
+3.90%+9.86%+96.91%+136.30% 1,098B
+0.99%+2.91%+51.05%+52.06% 631B
+0.78%+1.17%+25.21%+63.74% 438B
+0.23%+4.50%+51.77%+40.98% 368B
+0.30%+1.99%+32.35%+39.99% 298B
+0.46%+2.45%+8.99%+9.05% 251B
+1.52%+10.12%+44.75%+59.20% 226B
+1.15%+0.55%-4.12%-50.16% 209B
-0.11%+1.46%+11.43%+66.32% 165B
Average +0.08%+1,492.18%+61.16%+77.80% 368.68B
Weighted average by Cap. +0.13%+1,330.60%+52.20%+69.01%

Financials

2026 *2027 *
Net sales 233M 202M 189M 172M 325M 22.22B 330M 2.21B 867M 11.12B 875M 856M 37.02B 454M 393M 368M 336M 633M 43.34B 643M 4.31B 1.69B 21.68B 1.71B 1.67B 72.21B
Net income 56.53M 48.93M 45.74M 41.8M 78.78M 5.39B 80.01M 536M 210M 2.7B 212M 208M 8.98B 145M 126M 118M 107M 202M 13.85B 206M 1.38B 541M 6.93B 545M 533M 23.08B
Net Debt - -
Logo Precigen, Inc.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Employees
160
Date Price Change Volume
10/08/26 $7.000 -3.18% 4,753,488
07/08/26 $7.230 +4.63% 5,758,900
06/08/26 $6.910 +0.29% 7,269,947
05/08/26 $6.890 +5.51% 16,936,790
04/08/26 $6.530 -1.21% 8,015,238
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
7.000USD
Average target price
14.50USD
Spread / Average Target
+107.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PGEN Stock